• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Hims & Hers, Novo Nordisk partner to offer weight-loss drug Wegovy

April 30, 2025
in Medical Research
Reading Time: 4 mins read
A A
0
Hims & Hers, Novo Nordisk partner to offer weight-loss drug Wegovy
3
SHARES
7
VIEWS
Share on FacebookShare on Twitter



Direct-to-consumer virtual care company Hims & Hers is partnering with Novo Nordisk to allow Americans to access a bundled offering that includes the pharma giant’s obesity drug Wegovy and a Hims & Hers membership starting at $599 per month. 

Hims & Hers members will have direct access to NovoCare Pharmacy, an offering through Novo Nordisk that allows cash-paying individuals without insurance to obtain the medication Wegovy and Hims’ offerings, including 24/7 care, nutrition guidance and clinical support. 

Hims & Hers began offering Wegovy to cash-paying patients with a prescription this week.

The partners said they will also find a way to combine Novo Nordisk’s technologies with Hims & Hers’ ability to scale access to care.  

“We are pleased that Hims & Hers is making this offering available this week to people living with obesity,” Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk, said in a statement. 

“Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk’s innovative medications with Hims & Hers’ ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably.”

Additionally, Novo Nordisk announced it is also partnering with direct-to-consumer virtual care company Ro and publicly traded telemedicine company LifeMD to sell its weight-loss drug through the telehealth providers to cash-paying clients at a reduced cost of $499 per month.  

THE LARGER TREND

Wegovy was first approved as a weight loss drug in 2021. 

In May of last year, Hims & Hers announced it would add GLP-1 injections to its weight-loss offerings, which included generic and 503B compounded injectable medications and oral medication kits for weight management, priced starting at $199 a month.

Hims & Hers offered a compounded semaglutide, which the company’s website said was “a once-a-week prescription injection. Compounded GLP-1 injections available through Hims contain the same active ingredient as Ozempic and Wegovy.” 

The FDA raised concerns over unapproved versions of GLP-1 drugs, such as compounded semaglutides, as an option for weight loss.

Until February of this year, compounders were allowed to produce hundreds of thousands of doses of Novo’s brand-name medication due to a shortage of the medicine’s active ingredient, semaglutide.

However, in February, the FDA announced that Novo Nordisk could fully meet or exceed nationwide demand for all doses of Wegovy and its diabetes drug Ozempic and, therefore, declared an end to the supply shortage. 

In turn, larger outsourcing facilities that create compounded drugs were given a deadline of May 22 to stop making the drug, and smaller compounding pharmacies were to stop immediately.

Hims & Hers received backlash in response to an ad played during Super Bowl LIX earlier this year, in which it presented itself as a solution to America’s obesity problem. 

Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad failed to disclose safety and side effect information on compounded GLP-1 injections required in pharmaceutical advertising.

Last year, Hims & Hers announced plans to launch a generic version of Novo Nordisk’s GLP-1 diabetes drug liraglutide on its platform in 2025. 

Liraglutide, whose brand name is Victoza, is used to treat type 2 diabetes and is part of the GLP-1 agonists category, which can help with weight loss by curbing one’s appetite and controlling blood sugar. 



Direct-to-consumer virtual care company Hims & Hers is partnering with Novo Nordisk to allow Americans to access a bundled offering that includes the pharma giant’s obesity drug Wegovy and a Hims & Hers membership starting at $599 per month. 

Hims & Hers members will have direct access to NovoCare Pharmacy, an offering through Novo Nordisk that allows cash-paying individuals without insurance to obtain the medication Wegovy and Hims’ offerings, including 24/7 care, nutrition guidance and clinical support. 

Hims & Hers began offering Wegovy to cash-paying patients with a prescription this week.

The partners said they will also find a way to combine Novo Nordisk’s technologies with Hims & Hers’ ability to scale access to care.  

“We are pleased that Hims & Hers is making this offering available this week to people living with obesity,” Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk, said in a statement. 

“Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk’s innovative medications with Hims & Hers’ ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably.”

Additionally, Novo Nordisk announced it is also partnering with direct-to-consumer virtual care company Ro and publicly traded telemedicine company LifeMD to sell its weight-loss drug through the telehealth providers to cash-paying clients at a reduced cost of $499 per month.  

THE LARGER TREND

Wegovy was first approved as a weight loss drug in 2021. 

In May of last year, Hims & Hers announced it would add GLP-1 injections to its weight-loss offerings, which included generic and 503B compounded injectable medications and oral medication kits for weight management, priced starting at $199 a month.

Hims & Hers offered a compounded semaglutide, which the company’s website said was “a once-a-week prescription injection. Compounded GLP-1 injections available through Hims contain the same active ingredient as Ozempic and Wegovy.” 

The FDA raised concerns over unapproved versions of GLP-1 drugs, such as compounded semaglutides, as an option for weight loss.

Until February of this year, compounders were allowed to produce hundreds of thousands of doses of Novo’s brand-name medication due to a shortage of the medicine’s active ingredient, semaglutide.

However, in February, the FDA announced that Novo Nordisk could fully meet or exceed nationwide demand for all doses of Wegovy and its diabetes drug Ozempic and, therefore, declared an end to the supply shortage. 

In turn, larger outsourcing facilities that create compounded drugs were given a deadline of May 22 to stop making the drug, and smaller compounding pharmacies were to stop immediately.

Hims & Hers received backlash in response to an ad played during Super Bowl LIX earlier this year, in which it presented itself as a solution to America’s obesity problem. 

Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad failed to disclose safety and side effect information on compounded GLP-1 injections required in pharmaceutical advertising.

Last year, Hims & Hers announced plans to launch a generic version of Novo Nordisk’s GLP-1 diabetes drug liraglutide on its platform in 2025. 

Liraglutide, whose brand name is Victoza, is used to treat type 2 diabetes and is part of the GLP-1 agonists category, which can help with weight loss by curbing one’s appetite and controlling blood sugar. 

Previous Post

Maine lawmaker appeals to top court over state House censure for trans athlete post

Next Post

Government attempts to reduce environmental protections in planning bill could breach international law, says KC

Related Posts

World Health Assembly extends Global Strategy on Digital Health to 2027

World Health Assembly extends Global Strategy on Digital Health to 2027

May 24, 2025
4
genetics

Experts urge tighter sperm donation rules after cancer-linked gene passed to children

May 23, 2025
5
Next Post
An excavator working on pile of rubble near water shoreline and forest

Government attempts to reduce environmental protections in planning bill could breach international law, says KC

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

May 24, 2025
EU vows to defend interests after Trump threatens 50 percent tariffs

EU vows to defend interests after Trump threatens 50 percent tariffs

May 24, 2025
Druze ex-minister Kara discusses Israeli relations with Iraq, Syria

Druze ex-minister Kara discusses Israeli relations with Iraq, Syria

May 24, 2025
Monsoon reaches Kerala; marks earliest onset in over a decade

Monsoon reaches Kerala; marks earliest onset in over a decade todayheadline

May 24, 2025

Recent News

Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

May 24, 2025
3
EU vows to defend interests after Trump threatens 50 percent tariffs

EU vows to defend interests after Trump threatens 50 percent tariffs

May 24, 2025
4
Druze ex-minister Kara discusses Israeli relations with Iraq, Syria

Druze ex-minister Kara discusses Israeli relations with Iraq, Syria

May 24, 2025
3
Monsoon reaches Kerala; marks earliest onset in over a decade

Monsoon reaches Kerala; marks earliest onset in over a decade todayheadline

May 24, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

Aichi police arrest Nagoya teen for involvement in Myanmar fraud ring

May 24, 2025
EU vows to defend interests after Trump threatens 50 percent tariffs

EU vows to defend interests after Trump threatens 50 percent tariffs

May 24, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co